Statement Of Changes In Equity [Abstract]

Hyloris Pharmaceuticals SA - Filing #3166143

Concept 2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
Statement of changes in equity [abstract]
Statement of changes in equity [line items]
Equity
39,069,000 EUR
80,761,000 EUR
476,000 EUR
121,513,000 EUR
140,000 EUR
2,162,000 EUR
4,460,000 EUR
53,909,000 EUR
1,136,000 EUR
140,000 EUR
121,513,000 EUR
476,000 EUR
476,000 EUR
1,622,000 EUR
1,136,000 EUR
4,460,000 EUR
121,513,000 EUR
1,622,000 EUR
64,246,000 EUR
140,000 EUR
65,381,000 EUR
55,045,000 EUR
4,460,000 EUR
54,805,000 EUR
476,000 EUR
48,056,000 EUR
3,827,000 EUR
103,693,000 EUR
2,391,000 EUR
129,000 EUR
Changes in equity [abstract]
Comprehensive income [abstract]
Profit (loss)
15,380,000 EUR
11,906,000 EUR
Other comprehensive income
- EUR
- EUR
Comprehensive income
15,380,000 EUR
15,380,000 EUR
11,906,000 EUR
10,770,000 EUR
10,770,000 EUR
Issue of equity
5,000 EUR
- EUR
14,366,000 EUR
634,000 EUR
14,995,000 EUR
Increase (decrease) through share-based payment transactions, equity
540,000 EUR
540,000 EUR
560,000 EUR
560,000 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.